REPLHealthcare · BiotechnologyThe 8 Wall Street analysts covering Replimune Group, Inc. hold a median 12-month price target of $20 — +50.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 10 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Replimune Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (71): The shares have been drifting up relative to others.
Volatility (10): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on REPL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +50.9% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Aug 2026 | JP Morgan | Maintains | Overweight | $20 → $21 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $17 → $20 |
| 7 Aug 2026 | Wedbush | Upgrade | Outperform | — |
| 7 Aug 2026 | Wedbush | Upgrade | Outperform | $12 → $19 |
| 4 Aug 2026 | Leerink Partners | Upgrade | Outperform | — |
| 4 Aug 2026 | Leerink Partners | Upgrade | Outperform | $11 → $17 |
| 31 July 2026 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 31 July 2026 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 31 July 2026 | Wedbush | Maintains | Neutral | — |
| 31 July 2026 | Wedbush | Maintains | Neutral | $9.00 → $12 |
| 30 June 2026 | Wedbush | Maintains | Neutral | $6.00 → $9.00 |
| 30 June 2026 | Wedbush | Maintains | Neutral | — |
| 26 June 2026 | JP Morgan | Upgrade | Overweight | — |
| 1 June 2026 | Wedbush | Maintains | Neutral | — |
| 29 May 2026 | JP Morgan | Upgrade | Neutral | — |
| 13 Apr 2026 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 13 Apr 2026 | HC Wainwright & Co. | Downgrade | Sell | — |
| 13 Apr 2026 | Jefferies | Downgrade | Hold | — |
| 13 Apr 2026 | JP Morgan | Downgrade | Underweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. REPL appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Replimune Group, Inc. returned +115.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 8% of US stocks
Cheaper than 78% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 10% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Replimune Group, Inc. has a market value of $1.2B and an enterprise value of $1.2B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$297.0M.
Free cash flow in the twelve months to 30 June 2026: −$280.5M.
Trailing P/E: −3.8×; forward P/E: −6.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Replimune Group, Inc. employs 465 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Replimune Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
SBS Law reminds investors of a class action securities fraud lawsuit against Replimune Group, Inc., alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
Why it matters — Replimune shareholders may be affected by the securities fraud allegations and ensuing litigation against the company.
SBS Law reminds investors of a class action securities fraud lawsuit filed against Replimune Group for alleged violations of the Securities Exchange Act of 1934 and Rule 10b-5. The firm is urging REPL investors to consider leading the lawsuit.
Why it matters — A securities fraud lawsuit alleging Exchange Act violations introduces legal and reputational risk that could affect Replimune shareholders and the company's standing.
Glancy Prongay Wolke & Rotter LLP reminded Replimune Group, Inc. investors of the October 5, 2026 deadline to file a lead plaintiff motion in a securities fraud class action. The lawsuit covers investors who purchased Replimune securities between October 20, 2025 and April 10, 2026.
Why it matters — A REPL watcher would care because there is an active securities fraud class action against the company, with a lead plaintiff deadline approaching in October 2026.
The 8 Wall Street analysts covering Replimune Group, Inc. have a median 12-month price target of $20, with estimates ranging from $14 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Replimune Group, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Replimune Group, Inc. 34 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Sept 2026, Replimune Group, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (71 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +50.9% from the last close, and Ticker Nerd's factor model ranks Replimune Group, Inc. 34 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Replimune Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REPL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $24 over the next 12 months.
Replimune Group, Inc. returned +115.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer.
The most recent item we track (GlobeNewsWire, 8 Sept 2026): "REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law". SBS Law reminds investors of a class action securities fraud lawsuit against Replimune Group, Inc., alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its current work centers on engineered viral-based treatments designed to infect and destroy tumor cells while also stimulating an immune response against solid tumors. The company’s product pipeline includes therapies built on its proprietary RPx platform, with candidates aimed at multiple cancer settings. Replimune Group, Inc. serves the oncology market by advancing biologic approaches intended to complement or expand existing cancer treatment options. Headquartered in Woburn, Massachusetts, and founded in 2015, the company operates in the United States and the United Kingdom, with an emphasis on research, development, and commercialization of cancer immunotherapy programs.
CEO Dr. Sushil Patel Ph.D. · 465 employees · United States · https://www.replimune.com
